Findlay, Ohio – October 21, 2025 – PRESSADVANTAGE –
The RED Carpet Connection’s CEO, International neuroscientist, business consultant, and publicist, Dr. Andrea Adams-Miller, acted as one of the Phantoms in cult classic “The Rocky Horror Picture Show,” a live theatre production produced by 3B Productions at the historic Maumee Indoor Theater. The movie celebrated its 50th anniversary, making this live theatre production a fitting tribute. Additionally, this show hails as Dr. Adams-Miller’s seventy-eighth (78) theatrical production.
The Rocky Horror Picture Show has entertained audiences worldwide for half a century with its mix of science fiction, rock music, and comedy. This 3B Productions staging honored the original show’s eccentricity while inviting a new generation to experience the nuance of live theater.
The production was directed by Joe Barton, who led this staging and continued his multi-year history with 3B’s Rocky Horror. Janine Baughman directed the music, and the choreography was by Courtney Austin. Matthew Badyna served as assistant director, supported by Mitchell Antesky, Scott Antesky, and Sarah Kenney on crew, with Tom Miller as spotlight operator, all to enhance the production’s visual precision and rhythm. Additionally, Mark Pike assumed the role of Stage Manager, while Jesse Bernal assumed the role of Producer/Business Manager.
On the 50th anniversary, Director Joe Barton shared that 3B Productions’ decision to bring back the cult fiction was based on popular demand after a 5-year hiatus. Seven (7) original cast members returned to their previous roles or new roles.
The cast included Dylan Haught as Frank-N-Furter, a role originally made famous by Tim Curry in the 1975 film. Jordan Miller portrayed Columbia, first performed by Nell Campbell. Kailyn Jade Wilson took on the role of Magenta, originated by Patricia Quinn, while John Toth brought his background as an educator to Riff Raff, the character created by Richard O’Brien, who also wrote the musical.
Ben Tittl played Brad Majors, first portrayed by Barry Bostwick, and Annabell Welsh performed as Janet Weiss, initially played by Susan Sarandon. Marshall Kupresanin embodied Rocky, the character first brought to life by Peter Hinwood.
Matthew Badyna performed as Eddie, a role popularized by Meat Loaf, while also assisting with direction. Patrick Davis brought heart and humor to Dr. Scott, a role originally portrayed by Jonathan Adams, and Durrell Johnson served as the Narrator, drawing inspiration from Charles Gray’s distinctive delivery in the original production.
The Phantoms ensemble: Dr. Andrea Adams-Miller, Liz Badyna, Ashley Crawford, Caprice Crawford, Jen Crawford, Gus Coutinho, Joyce Coutinho, Emma Glover, Rylie Kregel, Megan Ledyard, Shannon Ruhe, Savanah Stephens, and Shylo Willcutt, contributed to the allure of the mysterious and electric show atmosphere.
Both Dr. Andrea Adams-Miller and Patrick Davis proudly list The Fort Findlay Playhouse in Findlay, Ohio, as their home theater, where they have performed in and supported numerous productions through the years.
“Every actor in this production gave new breath to the movie’s legacy,” said Dr. Andrea Adams-Miller. “The Rocky Horror Picture Show continues to remind us that creativity, self-expression, and community are timeless.”
About Dr. Andrea Adams-Miller:
Dr. Adams-Miller, CEO of TheREDCarpetConnection.com, serves as a Chief Strategic Influence Officer (CSIO) for corporations, entrepreneurs, athletes, celebrities, and influencers. In her professional work as a speaker, publicist, and neuroscientist, she draws from neuroscience, communication, and influence research to guide leaders in strengthening their communication and human connection. While her theater work exists apart from her consulting practice, she integrates performance with influence rooted in authenticity, emotion, and storytelling. All her stage time integrates the study and expression of brain science and communication psychology patterns applied to real-world leadership and media strategy.
###
For more information about TheREDCarpetConnection.com, contact the company here:
Dr. Andrea Adams-Miller Dr. Andrea Adams-Miller 4197226931 andreaadamsmiller@theredcarpetconnection.com 8155 Township Road 89
Oceanside, CA – October 22, 2025 – PRESSADVANTAGE –
Moment of Clarity has released a new educational resource, titled “Transcranial Magnetic Stimulation Side Effects,” now available on their website. The article offers an in-depth look at the possible side effects of TMS therapy, a noninvasive, FDA-approved treatment for depression, anxiety, and other mental health conditions. The resource helps patients, families, and communities understand the risks and benefits of TMS, offering clarity at a time when more people are exploring advanced mental health treatments.
The publication explains that TMS therapy utilizes magnetic pulses to stimulate specific areas of the brain associated with mood regulation. While widely regarded as safe and effective, patients often inquire about potential side effects before starting treatment. The article outlines how most side effects are mild, temporary, and well-tolerated, including scalp discomfort or headaches, which usually resolve quickly after sessions. Rare but more serious side effects, such as seizures, are discussed in context with their extremely low risk. By providing transparency, the resource encourages patients to consider TMS as part of a comprehensive treatment plan, rather than avoiding care due to uncertainty.
For individuals in Oceanside, California, seeking individual psychotherapy or couples therapy, this resource situates TMS within the broader spectrum of services that support recovery. Patients often benefit most when TMS is combined with evidence-based talk therapies and holistic approaches. For example, a patient may participate in individual psychotherapy to address underlying thought patterns, engage in couples therapy to improve communication, and involve loved ones in family therapy to strengthen support systems. A psychiatric evaluation often guides these treatment decisions, ensuring TMS is used appropriately alongside other services.
Communities surrounding Oceanside also benefit from access to this type of educational content. In neighborhoods such as El Camino Country Club and Calavera Hills, families frequently seek comprehensive mental health care that blends advanced treatments with counseling and supportive services. The resource reassures patients in these areas that TMS can be safely integrated with outpatient therapy and ongoing evaluations. For patients in Rancho Carlsbad and Carlsbad Village, where people often search for family therapy or psychiatric assessment for mental health, the publication emphasizes the importance of choosing programs that offer both traditional and advanced treatment options, ensuring care is tailored to the unique needs of each patient.
The article also explains that TMS therapy can be particularly effective for patients with treatment-resistant depression. In Oceanside and the surrounding suburbs, patients who have tried multiple medications without success may find TMS to be a promising option. The resource clarifies that TMS is not a replacement for therapy, but rather a complement, designed to improve symptoms sufficiently for patients to engage more fully in psychotherapy and other forms of care. This integration is crucial for families in Carlsbad Village and Calavera Hills, where patients often seek long-term solutions that address both immediate symptoms and deeper causes of mental health challenges.
Moment of Clarity’s publication further emphasizes that transparency about side effects builds trust between patients and providers. By addressing common concerns upfront, the article helps families in Rancho Carlsbad or El Camino Country Club feel more confident in exploring treatment. It highlights that informed patients are more likely to remain engaged in their care, leading to improved outcomes over time.
The resource also highlights the growing recognition that mental health recovery necessitates multiple approaches. For patients in Oceanside, this may include TMS therapy in conjunction with individual psychotherapy, couples therapy, or family therapy to ensure the entire support system is engaged. For people balancing complex needs, psychiatric evaluations provide the foundation for designing personalized care plans. The article emphasizes that advanced treatments, such as TMS, are most effective when they are part of a coordinated, evidence-based program.
By publishing Transcranial Magnetic Stimulation Side Effects, Moment of Clarity reinforces its commitment to patient education and evidence-based care. The resource not only explains the potential risks of TMS but also places them within the broader context of comprehensive mental health services. It provides practical information that patients and their families can use to make informed decisions, thereby reducing uncertainty and stigma surrounding advanced therapies.
For patients and families in Oceanside and nearby neighborhoods such as El Camino and Country Club, searching online for mental health in Oceanside, this new resource offers timely, accessible guidance. By combining clinical expertise with transparent information, Moment of Clarity helps patients and communities better understand TMS therapy, its potential side effects, and its role in supporting recovery.
###
For more information about Moment of Clarity Oceanside, contact the company here:
Moment of Clarity Oceanside Marie Mello (949) 288-2392 marie@momentofclarity.com 2215 Mesa Dr, Oceanside, CA 92054
WINTERTHUR, CH – October 10, 2025 – PRESSADVANTAGE –
OMN | Next Gen SEO & KI-Marketing Schweiz announces the expansion of its AI-powered marketing and SEO services specifically designed for Swiss businesses seeking sustainable growth without traditional advertising expenses. The company’s advanced technology platform combines artificial intelligence with semantic SEO techniques to deliver measurable results for companies operating in Switzerland’s multilingual market.
The Swiss digital marketing landscape continues to evolve rapidly as businesses seek more efficient ways to reach customers across German, French, and Italian-speaking regions. OMN’s comprehensive suite of AI-driven services addresses this challenge through automated lead generation, semantic copywriting, and neural data analysis that adapts to local market conditions.
“Swiss businesses require marketing solutions that understand the unique complexities of our multilingual market while delivering concrete results,” said E. Niederer, founder of OMN | Next Gen SEO & KI-Marketing Schweiz. “Our AI technology analyzes market patterns in real-time and automatically adjusts strategies to maximize return on investment for each client, regardless of their target region within Switzerland.”
The company’s approach integrates multiple advanced technologies, including AI-powered lead generation systems that promise a 300 percent increase in qualified contacts, semantic web architecture for improved search rankings, and automated content distribution across platforms. These innovations have positioned OMN at the forefront of Switzerland’s digital marketing transformation.
Recent implementations of OMN’s technology have demonstrated significant improvements in client performance metrics. The company’s semantic SEO methodology achieves top-10 search rankings within 90 days through algorithmic optimization and strategic link building. Additionally, their AI chatbot integration provides 24/7 lead qualification and customer service capabilities without manual intervention.
The expansion of services comes as Swiss businesses increasingly recognize the importance of data-driven marketing strategies. OMN’s Conversion Tracking & Analytics service provides transparent, real-time measurement of marketing activities, allowing companies to refine their efforts based on actual performance data rather than assumptions.
Beyond traditional digital marketing channels, OMN has developed partnerships within the Microsoft ecosystem, offering clients access to MSN, Bing, and Yahoo platforms. This diversification strategy helps Swiss businesses reach audiences that competitors often overlook while maintaining cost efficiency.
The company’s three-tier service structure – Momentum Structure, Cognition Framework, and Omniscale Suite – allows businesses of varying sizes to access AI marketing capabilities previously available only to large enterprises. Each tier incorporates neural data analysis, semantic data integration, and automated content production tailored to specific business needs.
OMN | Next Gen SEO & KI-Marketing Schweiz specializes in AI-powered marketing solutions for Swiss businesses. With over 17 years of experience, the company provides comprehensive digital marketing services, including semantic SEO, automated lead generation, and data analytics, designed specifically for Switzerland’s multilingual market environment. More news about the company can be found here: https://www.pressadvantage.com/story/78283-omn-leads-the-charge-in-next-gen-ai-marketing-seo-revolution-across-switzerland.
###
For more information about OMN | Next Gen SEO & KI-Marketing Schweiz, contact the company here:
OMN | Next Gen SEO & KI-Marketing Schweiz E. Niederer hello@omniederer.ch 8400 Winterthur Switzerland
London Borough of Croydon, England – October 23, 2025 – PRESSADVANTAGE –
Smile 4 U Dental Practice – Croydon has announced the availability of consultations for patients considering dentures as part of their restorative dental care. The initiative aims to help individuals who may have lost one or more teeth understand their replacement options in a comfortable and supportive environment.
The practice, which has become a well-known part of the local community, continues to focus on providing patient-centred dental care, offering both NHS and private treatments designed to suit a wide range of needs.
During these newly available denture consultations, patients have the opportunity to discuss how partial or full dentures might work for them, explore modern materials used in denture design, and understand the process involved in achieving a secure, natural-looking fit. The aim is to make sure that each patient receives clear information and guidance before making any treatment decisions. Those wishing to learn more about denture options and how they can restore function and appearance can visit: https://smile4u.co.uk/dentist-croydon/cosmetic-dentistry/dentures/.
The team at Smile 4 U Dental Practice – Croydon recognises that tooth loss can affect more than just appearance. It can also have an impact on speech, eating, and confidence. For this reason, the practice’s approach to dentures focuses on comfort, precision, and aesthetics. During the consultation, a dentist will typically review the patient’s oral health, discuss the most suitable type of denture, and outline what the fitting process involves.
Every stage, from the first impression to the final fit, is explained clearly to ensure patients understand what to expect. Modern dentures are designed to feel lighter, more secure, and more natural than older types, thanks to advances in dental materials and techniques. Patients can also discuss how best to maintain their dentures, with practical advice on cleaning, storage, and long-term care.
Beyond dentures, Smile 4 U Dental Practice – Croydon also offers consultations for a broader range of cosmetic dentistry treatments. These include options for improving the colour, alignment, and overall harmony of the smile. The practice’s cosmetic treatments are intended to blend aesthetics with oral health, ensuring that changes are both natural-looking and sustainable.
Consultations in this area often include a full oral examination, digital imaging where appropriate, and a discussion of achievable outcomes based on the patient’s individual goals. The focus remains on helping patients understand the possibilities without pressure or commitment. For readers who would like to explore the broader range of cosmetic dentistry options available at Smile 4 U Dental Practice, further details can be found at: https://smile4u.co.uk/dentist-croydon/cosmetic-dentistry/.
The practice places equal importance on routine and preventive care, maintaining its reputation as a trusted Croydon dental practice offering a welcoming environment for families and individuals alike. From regular check-ups and hygiene appointments to restorative and aesthetic treatments, the team prioritises personalised care that supports long-term oral health.
These denture consultations align with the practice’s broader goal of helping patients make informed decisions about their dental well-being. They provide a setting where patients can ask questions freely and receive professional advice tailored to their specific needs. The team understands that every case is unique and that replacing missing teeth can feel like a major step, which is why the consultation process is designed to be informative and unhurried.
The team’s ethos is rooted in the belief that restoring a smile should be as much about confidence and comfort as it is about clinical outcomes. Their ongoing investment in training and technology reflects a commitment to maintaining high standards while preserving the human side of dentistry.
For anyone in Croydon seeking to replace missing teeth, enhance their smile, or simply learn more about their oral health options, Smile 4 U Dental Practice is now welcoming new and existing patients for denture consultations. Additional information about the practice, its range of treatments, and how to arrange an appointment can be found at: https://smile4u.co.uk/dentist-croydon/.
###
For more information about Smile 4 U – Croydon, contact the company here:
Smile 4 U – Croydon Maryam Shahid +44-20-8640-7586 info@smile4u.co.uk Smile 4 U – Croydon, 357 Addiscombe Road, Croydon CR0 7LG, United Kingdom
As temperatures begin to drop across North Texas, many commercial property owners are turning their attention to the performance and dependability of their heating and cooling systems. Comfort Conditioning, a locally based HVAC service provider, weighs in when it comes to helping business owners understand the importance of prioritizing system maintenance and repairs to ensure optimal efficiency throughout the fall and winter months. The company’s dedicated team provides specialized solutions through its Commercial HVAC Repair program, designed to help commercial operations maintain reliable performance and energy efficiency year-round. With seasonal temperature swings common in the region, consistent system reliability has become a key factor for commercial operations aiming to maintain both energy efficiency and occupant comfort.
According to Kanon Van Guilder, owner of Comfort Conditioning in Krum, Texas, regular maintenance and prompt attention to system issues can make a substantial difference in preventing costly breakdowns during critical periods of operation. The company’s commercial division provides a comprehensive range of professional services tailored to meet the demanding requirements of businesses across multiple industries. These services focus on accurate diagnostics, efficient repairs, and ongoing maintenance strategies that enhance both performance and longevity. By addressing issues such as airflow imbalances, component wear, and energy inefficiencies, businesses can sustain consistent indoor comfort while reducing operational disruptions and unplanned expenses.
Commercial HVAC systems often face heavier usage loads than residential units, requiring precise calibration and maintenance routines to sustain performance. As North Texas experiences fluctuating autumn temperatures that can strain both heating and cooling components, many facility managers are scheduling inspections to prepare for the shift to cooler conditions. A spokesperson for Comfort Conditioning emphasized that proactive maintenance during this transitional period is essential to avoiding disruptions in business operations.
“Commercial HVAC systems are the backbone of a comfortable and productive environment,” said Kanon Van Guilder. “When equipment is neglected or allowed to operate inefficiently, the results can lead to energy waste, premature component failure, and costly downtime.” Van Guilder noted that consistent inspection intervals and data-driven repair decisions are among the most effective strategies for extending system lifespan.
For businesses in sectors such as retail, healthcare, and manufacturing, reliable indoor climate control directly impacts employee performance, equipment safety, and customer satisfaction. Even a short disruption can have measurable consequences, from lost productivity to increased energy consumption when systems must compensate for deferred maintenance. Detailed evaluations that include airflow analysis, filter and coil inspections, and verification of electrical and mechanical integrity are important steps to collectively support efficient operation and energy savings.
Van Guilder explained that many business owners underestimate how early warning signs can escalate. “Unusual noises, inconsistent temperatures, or spikes in utility bills often point to underlying system inefficiencies,” he said. “Addressing these issues promptly allows our clients to avoid full system failures and the resulting loss of comfort or business continuity. Every commercial system requires a customized approach based on usage, square footage, and environmental demands.”
As North Texas businesses prepare for an anticipated increase in heating requirements, energy efficiency remains a critical concern. Aging equipment and deferred maintenance can lead to higher operating costs, even when systems appear to be functioning adequately. Comfort Conditioning’s technicians use diagnostic tools to assess performance metrics such as airflow resistance, refrigerant levels, and heat exchanger condition, identifying opportunities for improved efficiency. By aligning maintenance with operational goals, commercial clients can achieve measurable returns through reduced energy consumption and fewer emergency service calls.
Van Guilder added that many facilities are also exploring system upgrades that integrate modern control technologies and variable-speed components. “Intelligent systems can make real-time adjustments based on building occupancy and temperature fluctuations,” he said. “That level of precision not only improves comfort but also reduces energy waste. Incorporating these technological advancements is becoming more common as part of an overall facility management strategy.”
While system upgrades can offer long-term savings, Comfort Conditioning maintains that maintenance remains the cornerstone of reliability. Routine servicing provides an opportunity to identify and correct inefficiencies before they escalate into expensive repairs. For facilities that operate extended hours or house sensitive equipment, consistent HVAC performance is not merely a matter of comfort—it is essential to business continuity. The company’s technicians are trained to provide service recommendations that balance immediate operational needs with long-term financial efficiency.
Commercial property managers across North Texas have increasingly adopted preventative maintenance agreements as a safeguard against unplanned outages. These agreements allow businesses to schedule routine service checks that align with seasonal changes, ensuring readiness for both heating and cooling demands throughout the year. Van Guilder emphasized that clients who adopt such programs experience fewer emergencies and enjoy more predictable operating budgets. “Preventive maintenance is about control,” he said. “It allows our clients to manage costs, plan ahead, and avoid the unpredictability that comes from reactive repairs.”
In addition to reliability and cost management, environmental considerations are playing a growing role in commercial HVAC decisions. As regulatory standards continue to evolve, energy-efficient systems are becoming a practical and responsible investment for business owners seeking to reduce their carbon footprint. Comfort Conditioning’s commercial repair and maintenance services support compliance with modern energy standards, helping clients achieve both sustainability and operational performance.
Van Guilder concluded by noting that HVAC reliability extends beyond mechanical function—it represents a commitment to operational excellence. “A well-maintained system reflects a business that values safety, efficiency, and comfort,” he said. “As cooler temperatures approach, we encourage every business owner to take a proactive step toward ensuring their HVAC systems are ready to perform when it matters most.”
SAN BERNARDINO, CALIFORNIA / ACCESS Newswire / October 27, 2025 / Dateline Resources Limited (ASX:DTR)(OTCQB:DTREF)(FSE:YE1) (Dateline or the Company) is pleased to provide an update on the drilling activities underway at its 100%-owned Colosseum Gold-REE Project in California, USA.
Three drill rigs are currently operating on site, one diamond rig and two reverse circulation (RC) rigs and until recently, the program was supported by an additional sonic rig that has now completed its tailings stability work and has been demobilised.
The current drilling phase is focused on compact infill, extensional, geotechnical, and tailings stability holes as part of the Bankable Feasibility Study (BFS). The broader program will shortly transition to testing several newly defined, high-priority gold and rare earth targets identified from recent geophysical and geochemical work across the Colosseum system.
Highlights
BFS Drilling: The compact BFS drill program of 32 holes for 4,257 metres (13,968 feet) is 67% complete with an estimated end date of November 7, 2025.
Stockpile Drilling: Approximately 1Mt of historical stockpiles grading ~1 g/t Au will be RC drilled to confirm grade continuity and support inclusion in the mine plan, potentially adding already mined ~30,000oz of gold to the feasibility inventory.
Tailings Stability Drilling: A sonic drilling program over the existing tailings storage facility was completed, confirming the foundation is stable and suitable for additional lifts as part of the planned development.
Exploration Targets: The major phase of the drilling campaign will focus on newly defined gold and rare earth targets, with both programs to be drilled concurrently. Drilling will begin on the high-priority gold breccia pipe targets (Targets 1, 5 and 6) alongside the 2200N REE target, the first of three defined anomalies to be tested.
Dateline’s Managing Director, Stephen Baghdadi, commented:“Having multiple rigs on site has allowed us to accelerate the program so we can focus our efforts sooner on the new gold and rare earth targets. With over 1,400 samples already at the lab, we look forward to reporting the results as they become available and are analysed.
“Our geology team is eager to commence drilling the new gold and REE targets in early November.”
BFS Drill Program Status
Infill and Extensional Program
The Scoping Study outlined 16.6 Mt of ore, with 81% classified as Measured and Indicated and the remaining 19% as Inferred. The current drill program is designed to infill these Inferred areas and support upgrades to Indicated or Measured categories, providing greater confidence in mine scheduling and production planning.
The infill component comprises 32 holes for 4,257 metres (13,968 feet) and is now 67% complete. Samples from the completed holes have been dispatched to ALS Reno for analysis.
Figure 1: RC rig infill drilling the North Pipe at Colosseum
Stockpile Drilling
When Dateline acquired the Colosseum Project in 2021, it inherited an existing ore stockpile left on site following the suspension of operations in 1993. Historical mine records indicate the stockpile contains approximately 1Mt grading 1.0 g/t Au for an estimated 30,000 ounces of gold.
To date, Dateline’s work has focused on expanding the in-situ Mineral Resource, and the stockpile has not yet been drilled or included in the current mine plan. The Company now intends to complete reverse-circulation (RC) drilling to confirm the tonnes and grade of this material, enabling it to be incorporated into the development schedule.
This mined stockpile has the potential to be processed during the commissioning phase of the operation, providing an early source of mill feed, accelerating gold production, and enhancing overall project economics.
Figure 2: Stockpiles to be assessed with RC drilling
Tailings Stability Drilling
Dateline plans to reutilise the existing tailings storage facility (TSF) at Colosseum as part of the proposed mine development. The design involves filter pressing the tailings prior to deposition, allowing the material to be stacked dry on top of the existing facility. This approach enables water recirculation, significantly reducing overall water consumption and supporting construction of additional TSF lifts.
To confirm the suitability of this approach, a program of sonic drilling was completed across the TSF site. The recovered core was reviewed by the Company’s hydrogeological consultants, who have provided their findings to the BFS team. Results confirmed the foundation stability and suitability of the existing TSF for future use as a dry-stack tailings and waste rock facility.
Figure 3: Sonic drill rig on site at the Colosseum TSF
Figure 4: Existing TSF area drilled with sonic drilling
New Target Drilling
The BFS drilling programs were prioritised for completion ahead of the new target testing, as they form part of the critical path for the Colosseum development timeline. With these programs now nearing completion, the focus is shifting to the next phase of drilling-testing the newly defined gold and rare earth element (REE) targets.
Dateline has ranked several high-priority targets for initial assessment, with Gold Targets 1, 5 and 6 and REE Target 2200N to be drilled first as part of the expanded exploration campaign.
Figure 5: New Target Drilling with gold targets 1, 5 and 6 and REE target 2200N shown
This ASX announcement has been authorised for release by the Board of Dateline Resources Limited.
Dateline Resources Limited (ASX: DTR, OTCQB: DTREF, FSE: YE1) is an Australian company focused on mining and exploration in North America. The Company owns 100% of the Colosseum Gold-REE Project in California.
The Colosseum Gold Mine is located in the Walker Lane Trend in East San Bernardino County, California. On 6 June 2024, the Company announced to the ASX that the Colosseum Gold mine has a JORC-2012 compliant Mineral Resource estimate of 27.1Mt @ 1.26g/t Au for 1.1Moz. Of the total Mineral Resource, 455koz @ 1.47/t Au (41%) are classified as Measured, 281koz @1.21g/t Au (26%) as Indicated and 364koz @ 1.10g/t Au (33%) as Inferred.
On 23 May 2025, Dateline announced that updated economics for the Colosseum Gold Project generated an NPV6.5 of US$550 million and an IRR of 61% using a gold price of US$2,900/oz.
The Colosseum is located less than 10km north of the Mountain Pass Rare Earth mine. Planning has commenced on drill testing the REE potential at Colosseum.
Dateline has also acquired the high-grade Argos Strontium Project, also located in San Bernadino County, California. Argos is reportedly the largest strontium deposit in the U.S. with previous celestite production grading 95%+ SrSO4.
Forward-Looking Statements
This announcement may contain “forward-looking statements” concerning Dateline Resources that are subject to risks and uncertainties. Generally, the words “will”, “may”, “should”, “continue”, “believes”, “expects”, “intends”, “anticipates” or similar expressions identify forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond Dateline Resources’ ability to control or estimate precisely, such as future market conditions, changes in regulatory environment and the behaviour of other market participants. Dateline Resources cannot give any assurance that such forward-looking statements will prove to have been correct. The reader is cautioned not to place undue reliance on these forward-looking statements. Dateline Resources assumes no obligation and does not undertake any obligation to update or revise publicly any of the forward-looking statements set out herein, whether as a result of new information, future events or otherwise, except to the extent legally required.
Competent Person Statement
Sample preparation and any exploration information in this announcement is based upon work reviewed by Mr Greg Hall who is a Chartered Professional of the Australasian Institute of Mining and Metallurgy (CP-IMM). Mr Hall has sufficient experience that is relevant to the style of mineralization and type of deposit under consideration and to the activity which he is undertaking to qualify as a Competent Person as defined in the 2012 Edition of the “Australasian Code for Reporting Exploration Results, Mineral Resources and Ore Reserves” (JORC Code). Mr Hall is a Non-Executive Director of Dateline Resources Limited and consents to the inclusion in the report of the matters based on this information in the form and context in which it appears.
Company Confirmations
The Company confirms it is not aware of any new information or data that materially affects the information included in the announcements dated 23 October 2024 with regard to the Colosseum MRE and 23 May 2025 with regard to Colosseum Project Economics. Similarly, the Company confirms that all material assumptions and technical parameters underpinning the estimates and the forecast financial information referred to in those previous announcements continue to apply and have not materially changed.
Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing endoscopic improvement versus placebo
Updated ANTHEM-UC data support Phase 3 clinical development of icotrokinra in both moderately to severely active ulcerative colitis and Crohn’s disease
In areas of high impact, 72% of patients with scalp psoriasis and 85% with genital psoriasis treated with icotrokinra achieved site-specific clear or almost clear skin at Week 52 in Phase 3 ICONIC-TOTAL study
Further, 67% of patients treated with icotrokinra in the ICONIC-TOTAL study achieved overall rates of clear or almost clear skin by Week 24, which was maintained through Week 52
NEWARK, CALIFORNIA / ACCESS Newswire / October 27, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) today announced new data from two studies of icotrokinra, a first-in-class investigational targeted oral peptide that precisely blocks the IL-23 receptor, presented at two recent medical conferences.
Week 28 data from the Phase 2b ANTHEM-UC study of icotrokinra will be presented at the 2025 American College of Gastroenterology Annual Scientific Meeting (ACG), demonstrating sustained and clinically meaningful results, with all doses (100 mg, 200 mg and 400 mg) showing higher rates of clinical response a , clinical remission b , endoscopic improvement c and histologic-endoscopic mucosal improvement (HEMI) d at Week 28 compared to placebo. [1] These outcomes build on Week 12 data that was recently presented at United European Gastroenterology (UEG) Week 2025.
Icotrokinra 400 mg once daily
Week 12
Week 28
Placebo (at Week 28)
Clinical response 1
63.5%
66.7%
25.4%
Clinical remission 1
30.2%
31.7%
9.5%
Endoscopic improvement 1
36.5%
38.1%
11.1%
HEMI rates 1
28.6%
33.1%
11.1%
Based on results from the Phase 2b ANTHEM-UC study, Johnson & Johnson has initiated the ICONIC-UC Phase 3 protocol in adults and adolescents with moderately to severely active UC, as well as the ICONIC-CD Phase 2b/3 protocol in adults with moderate to severely active Crohn’s disease.
Additionally, new long-term 52-week data from the Phase 3 ICONIC-TOTAL study e , presented last week at the 2025 Fall Clinical Dermatology Conference, show icotrokinra demonstrated high and durable rates of site-specific psoriasis clearance affecting these high-impact and difficult-to-treat areas of the body. [2]
72% of patients with scalp psoriasis achieved a scalp-specific Investigator’s Global Assessment (ss-IGA) 0/1 score and 57% achieved ss-IGA 0 f
85% of patients with genital psoriasis achieved a Physician’s Global Assessment of Genitalia (sPGA-G) 0/1 and 73% achieved sPGA-G 0 g
In the smaller subset of patients with hand/foot psoriasis, treatment with icotrokinra showed a numerically higher rate of skin clearance at Week 16, which increased through Week 52 with patients achieving a hand and/or foot Physician’s Global Assessment (hf-PGA) h score of 0/1 increasing from 42% to 62%.
Overall response rates among patients treated with once-daily icotrokinra were maintained through Week 52, with 67% of patients treated with icotrokinra achieving clear or almost clear skin (Investigator’s Global Assessment (IGA) i 0/1) and 44% achieving completely clear skin (IGA 0) at Week 52. The overall response rates were also comparable among patients who received icotrokinra for all 52 weeks and those who transitioned from placebo to icotrokinra at Week 16 (67% versus 68% achieved IGA0/1, respectively). Across treatment groups, adverse event and serious adverse event rates were similar through Week 52 compared to those through Week 16, with no new safety signals identified.
“Additional data from Phase 2b ANTHEM-UC and Phase 3 ICONIC-TOTAL studies continue to show a strong durability of response and clinical benefit of icotrokinra treatment in a range of inflammatory and immunological diseases,” said Dinesh V. Patel, Ph.D., President and Chief Executive Officer at Protagonist. “We are very pleased to see that the ICONIC development program now includes both ICONIC-UC, a Phase 3 study in adults with moderately to severely active UC, and ICONIC-CD, a Phase 2b/3 study in adults with moderate to severely active Crohn’s disease. Our goal continues to be delivering well-differentiated oral targeted therapy treatments for patients as we continue to advance our oral peptides-based scientific and innovation leadership in the I&I field.”
Editor’s notes:
Clinical response was defined as a decrease from baseline in the modified Mayo score by greater than or equal to (>=) 30 percent (%) and >=2 points, with either a >=1-point decrease from baseline in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1.
Clinical remission was defined as a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1.
Endoscopic improvement was defined as an endoscopy subscore of 0 or 1.
Histologic-endoscopic mucosal improvement (HEMI) was defined as histologic remission (absence of neutrophils from the mucosa in both lamina propria and epithelium, no crypt destruction, and no erosions, ulcerations, or granulation tissue according to the Geboes grading system) and endoscopic improvement (MES of 0 or 1).
ICONIC-TOTAL evaluates the efficacy and safety of icotrokinra compared with placebo in participants with at least moderate scalp, genital, and/or hand/foot PsO with once-daily icotrokinra or placebo, with placebo-to-icotrokinra transition at Week 16.
The ss-IGA is a five-point scale where scalp lesions are assessed in terms of clinical signs of redness, thickness, and scaliness on a severity score ranging from 0 to 4, where 0 indicates absence of disease, 1 is very mild, 2 is mild, 3 is moderate and 4 indicates severe disease.
The sPGA-G is a six-point scale used to evaluate the severity of genital psoriasis at a given time point ranging from 0 to 5, where 0 indicates clear, 1 is minimal, 2 is mild, 3 is moderate, 4 is severe and 5 indicates very severe disease. [3]
The Physician’s Global Assessment of Psoriasis on the Hands and/or Feet (hf-PGA) assesses the severity of hand and foot psoriasis using a 5-point scale to score the plaques on the hands and feet as: clear (0), almost clear (1), mild (2), moderate (3) and severe (4). [4]
The IGA is a five-point scale with a severity score ranging from 0 to 4, where 0 indicates clear, 1 is minimal, 2 is mild, 3 is moderate, and 4 indicates severe disease. [5]
About ANTHEM-UC
ANTHEM-UC ( NCT06049017 ) is a Phase 2b multicenter, randomized, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of icotrokinra (JNJ-77242113, JNJ-2113) in patients with moderately to severely active ulcerative colitis who had an inadequate response or intolerance to conventional therapy (e.g., thiopurines or corticosteroids), prior biologics (TNF antagonists or vedolizumab) and/or ozanimod or approved JAK inhibitors. The study is evaluating three once-daily dosages of icotrokinra taken orally. Participants who complete the Week 28 assessments and have achieved clinical response at Week 28 and who, in the opinion of the investigator, will continue to benefit from treatment with study intervention will continue in the 48-week long term extension (LTE) period and receive the same treatment up to Week 76.
About Ulcerative Colitis Ulcerative colitis (UC) is a chronic disease of the large intestine, also known as the colon, in which the lining of the colon becomes inflamed and develops tiny open sores, or ulcers, that produce pus and mucus. It is the result of the immune system’s overactive response.Symptoms vary but may typically include loose and more urgent bowel movements, rectal bleeding or bloody stool, persistent diarrhea, abdominal pain, loss of appetite, weight loss, and fatigue.
About the ICONIC Clinical Development Program The pivotal Phase 3 ICONIC clinical development program of icotrokinra (JNJ-2113) in adult and pediatric patients 12 years of age and older with moderate-to-severe plaque PsO was initiated with two studies in Q4 2023 – ICONIC-LEAD and ICONIC-TOTAL – pursuant to the license and collaboration agreement between Protagonist Therapeutics, Inc. and Janssen Biotech, Inc., a Johnson & Johnson company.
ICONIC-LEAD ( NCT06095115 ) is a RCT to evaluate the efficacy and safety of icotrokinra compared with placebo in participants with moderate-to-severe plaque PsO, with PASI 90 and IGA score of 0 or 1 with at least a 2-grade improvement as co-primary endpoints.
ICONIC-TOTAL ( NCT06095102 ) is a RCT to evaluate the efficacy and safety of icotrokinra compared with placebo for the treatment of PsO in participants with at least moderate severity affecting special areas (e.g., scalp, genital, and/or hands and feet) with overall IGA score of 0 or 1 with at least a 2-grade improvement as the primary endpoint.
Other Phase 3 studies in the development program include ICONIC-ADVANCE 1 ( NCT06143878 ) and ICONIC-ADVANCE 2 ( NCT06220604 ), which are evaluating the efficacy and safety of icotrokinra compared with both placebo and deucravacitinib in adults with moderate-to-severe plaque PsO. ICONIC-ASCEND will evaluate the efficacy and safety of icotrokinra compared with placebo and ustekinumab in participants with moderate-to-severe plaque psoriasis. ICONIC-PsA 1 ( NCT06878404 ) and ICONIC-PsA 2 ( NCT06807424 ) will evaluate the efficacy and safety of icotrokinra compared to placebo in participants with active psoriatic arthritis.
Johnson & Johnson has also initiated the ICONIC-UC Phase 3 protocol in adults and adolescents with moderately to severely active UC as well as the ICONIC-CD Phase 2b/3 protocol in adults with moderate to severely active Crohn’s disease.
About Plaque Psoriasis Plaque psoriasis (PsO) is a chronic immune-mediated disease resulting in overproduction of skin cells, which causes inflamed, scaly plaques that may be itchy or painful. It is estimated that 8 million Americans and more than 125 million people worldwide live with the disease. Nearly one-quarter of all people with plaque PsO have cases that are considered moderate-to-severe.Plaques typically appear as raised patches with a silvery white buildup of dead skin cells or scales.Plaques may appear red in lighter skin or more of a purple, gray or dark brown color in patients with darker skin tones. Plaques can appear anywhere on the body, although they most often appear on the scalp, knees, elbows, and torso.Living with plaque PsO can be a challenge and impact life beyond a person’s physical health, including emotional health, relationships, and handling the stressors of life. Psoriasis on highly visible areas of the body or sensitive skin, such as the scalp, hands, feet, and genitals, can have an increased negative impact on quality of life.
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist’s proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application (NDA) for icotrokinra submitted to the FDA in July and in the NDA submission for rusfertide expected by end of 2025. Icotrokinra (formerly, JNJ-2113), is a first-in-class investigational targeted oral peptide that precisely blocks the Interleukin-23 receptor (“IL-23R”) which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra’s joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies’ IL-23R collaboration, Protagonist was primarily responsible for the development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and the oral hepcidin program.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company’s website at https://www.protagonist-inc.com/ .
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of icotrokinra, and expectations regarding the icotrokinra development program. In some cases, you can identify these statements by forward-looking words such as “anticipate,” “believe,” “may,” “will,” “expect,” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Johnson & Johnson and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading “Risk Factors” contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.
[1] Jairath V., et al. Efficacy and Safety of Icotrokinra, a Targeted Oral Peptide That Selectively Blocks IL-23 Receptor Activation, In Ulcerative Colitis: Results From Week 28 of ANTHEM-UC, a Phase 2b Dose-ranging Trial. Poster 1066 at ACG Annual Scientific Meeting 2025. October 2025.
[2] Lain, E et al. Durability of Response to the Targeted Oral Peptide Icotrokinra for High-Impact Site Psoriasis: 1-Year ICONIC-TOTAL Findings. Oral presentation (Presentation FC01.1G) at the 2025 Fall Clinical Dermatology Conference. October 2025.
[3] Merola JF, Bleakman AP, Gottlieb AB, et al. The Static Physician’s Global Assessment of Genitalia: a clinical outcome measure for the severity of genital psoriasis. J Drugs Dermatol . 2017;16(8):793-799
[4] Goldblum O, et al. Validation of the physician’s global assessment of psoriasis of the hands and/or feet as a clinical endpoint. J Am Acad Dermatol. 2013:68(4)Supplement1:AB218.
[5] Simpson E, Bissonnette R, Eichenfield LF, et al. The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis [published online April 25, 2020]. J Am Acad Dermatol. doi: 10.1016/j.jaad.2020.04.104. Accessed April 2025.
VANCOUVER, BC / ACCESS Newswire / October 27, 2025 / Avino Silver & Gold Mines Ltd. (TSX:ASM)(NYSE American:ASM)(FSE:GV6) (“Avino” or “the Company”) reports results of four additional drill holes from La Preciosa which were drilled to twin previous drilling. Assay results for the intercepts of the La Gloria and Abundancia veins continued to be very positive and are shown in Table 1. Previous drill results can be found here .
Selected Intercept Highlights:
Hole PMLP 25-06: 787 g/t Ag and 0.51 g/t Au over 5.22 metres true width
including 3,206 g/t Ag and 1.02 g/t Au over 0.77 metres true width
Hole PMLP 25-08 at Gloria: 306 g/t Ag and 1.15 g/t Au over 3.98 metres true width
including 699 g/t Ag and 5.80 g/t Au over 0.63 metres true width
Hole PMLP 25-08 at Abundancia: 463 g/t Ag and 0.61 g/t Au over 4.00 metres true width
including 642 g/t Ag and 0.60 g/t Au over 0.95 metres true width
Based on previous drill results, the variation of grades and thicknesses within relatively short distances (under 10 metres) compared with previously drilled intercepts were expected due to the “pinch and swell” geometry of the La Preciosa veins and the high nugget effects. The drill results exceeded grade expectations and verified the geometry of the current vein-based resource model.
“We’re excited to share continued strong results from four new drill holes at La Preciosa, each returning excellent grades that exceed the current resource average. These results reinforce the strategy of using underground mining methods to unlock the value of the deposit” said David Wolfin, President and CEO. “Notably, the wider intercepts at La Gloria and Abundancia highlight the deposit’s potential, especially early in the mine life. We’ll continue to refine our geological model, expand drilling into underexplored areas, and integrate ongoing channel sampling data as development advances on both veins, in both direction at level 3.”
Drilling Results
Assays were received on four holes totalling 915 metres drilled at La Preciosa, intersecting the La Gloria vein in all four holes, the Abundancia vein in three holes, and additional unnamed and splay veins in one of the holes. Assays were processed under Avino’s standard QA/QC program, with no indications of bias or contamination detected. Unlike the Avino Mine, the La Preciosa deposit contains no notable copper mineralization, so no copper values are reported.
Details are shown in the table and images below.
Table 1 – Summary Drill Results
Structure
Hole Number
From (m)
To (m)
Intercept Length (m)
True width (m)
Au (g/t)
Ag (g/t)
AgEq ¹ (g/t)
La Gloria
PMLP-25-05
223.25
226.45
3.2
2.48
0.66
425
484
Including
225.7
226.45
0.75
0.58
1.60
1299
1441
Abun Splay 1
PMLP-25-05
234.5
237.6
3.1
3.07
0.16
34
48
Abundancia
PMLP-25-05
303.75
304.55
0.8
0.78
1.21
513
621
Unnamed_5
PMLP-25-05
221.3
221.8
0.5
0.40
1.02
455
546
Unnamed_6
PMLP-25-05
261.71
263.06
1.35
0.90
0.29
74
100
La Gloria
PMLP-25-06
169.8
176.6
6.8
5.22
0.51
787
832
Including
174.45
175.45
1
0.77
1.02
3206
3297
Abundancia
PMLP-25-06
219.4
220.9
1.5
1.47
0.86
635
711
La Gloria
PMLP-25-07
175.9
181.7
5.8
2.84
0.39
216
251
Including
176.93
178
1.07
0.52
0.35
490
521
Abundancia
PMLP-25-07
227.2
227.75
0.55
0.52
0.24
93
114
La Gloria
PMLP-25-08
53.15
58.5
5.35
3.98
1.15
306
408
Including
53.15
54.00
0.85
0.63
5.80
699
1215
Abundancia
PMLP-25-08
135.60
139.80
4.20
4.00
0.61
463
517
Including
136.6
137.6
1
0.95
0.60
642
696
AgEq in drill results above assumes $4000/oz Au and $45.00/oz Ag, and 100% metallurgical recovery.
Figure 1 – Plan View of the La Gloria Vein Showing the Current Drill Hole Locations and the Twin Hole Locations as well as the Projected View of the Decline and Surface Works.
Figure 2 – Longitudinal View of the La Gloria Vein Showing the Current Holes (highlighted) Relative to the Historic Drilling.
Figure 3 – Longitudinal View of the Abundancia Vein Showing the Current Holes (highlighted) Relative to the Historic Drilling.
Figure 4 – Cross-Section of PMLP25-08, looking North, Showing the Abundancia Vein, the La Gloria vein and the Projections of the Decline Ramp.
Geological Description
La Preciosa deposit is situated on the eastern flank of the Cretaceous to mid-Tertiary Sierra Madre Occidental. The SMO is the largest silicic igneous province in North America, and it stretches from the USA-Mexico border to the latitude of Guadalajara, where the SMO is covered by the late Miocene to Quaternary Trans-Mexican Volcanic Belt.
Mineralization at the La Preciosa is hosted within multiple discrete poly-phase quartz veins, often displaying banded, smoky, drusy, and chalcedonic textures. Also, in each stage, there is variably crustiform banded fracture fill/breccia cement mineralogy. Fluorite, amethyst, a substantial number of barite laths, calcite, and rhodochrosite may also be present, and sulphide mineralization in the form of sphalerite, galena, pyrite, chalcopyrite, acanthite, sparse native silver, and free gold, as well as iron and manganese oxides have been noted in drill core. The principal silver-bearing mineral at the La Preciosa is acanthite-pseudomorphic after argentite or as microcrystalline to amorphous grains.
The main vein system on the Abundancia ridge consists of dominantly north-south-striking and westward-dipping veins plus east-southeast-striking, south-dipping crosscutting veins. The Abundancia vein system has been traced on the surface for over 1.5 km. In the eastern part of the Project, a north- to northwest-striking, shallow west-dipping vein system with associated hanging wall veining and alteration is exposed in a series of hills. This vein system is referred to as the Martha vein and has been traced by drilling for over 2.5 km along the strike.
The mineralization in the area occurs in veins, veinlets, and stockwork. These veins average in true width less than 15 m (Martha Vein) and consist of several stages of banded crustiform to colloform, quartz (and cryptocrystalline quartz at shallow depths), adularia, barite, and typically later carbonates (both calcite and rhodochrosite); illite commonly replaces the adularia. There are variable amounts of pyrite, sphalerite, and galena plus argentite, and variable amounts of tetrahedrite – tennantite, freibergite, and Ag sulfosalt.
There are steep-dipping veins in the west, such as the La Gloria vein. These steep veins can be considered as a mineralized zone or lode of stock work, silicification, breccias, veins, vein breccias, veinlets, and a general mix of multiple styles of mineralization.
The mineralization displays characteristics typical of epithermal veins in Mexico, particularly of the Ag-rich variety. Quartz veins are accompanied by adularia, barite, calcite, and rhodochrosite of variable timing, as well as acanthite, freibergite, Ag sulfosalts and minor electrum, plus variable amounts of pyrite, honey-coloured sphalerite, tennantite/tetrahedrite, chalcopyrite and galena, and supergene Fe and Mn oxides; the hypogene minerals are characteristic of intermediate-sulphidation deposits in Mexico. Mineralization is believed to be Tertiary in age, and both the Lower Volcanic Supergroup (LVS) and Upper Volcanic Supergroup (UVS) are mineralized, but the overlying basalts are recent and not mineralized.
Sampling and Assay Methods
Following detailed geological and geotechnical logging, selected drill core areas were cut in half. One half of the core was submitted to the SGS Laboratory facility in Durango, Mexico, and the other half was retained on-site for verification and reference. Gold is assayed by fire assay with an AA finish. Any samples exceeding 3.0 gold g/t are re-assayed and followed by a gravimetric finish. Multi-element analyses are also completed for each sample by SGS ICP14B methods. Silver is fire assayed with a gravimetric finish for samples assaying over 100 g/t. Avino uses a series of standard reference materials, blank reference materials, and duplicates as part of their QA/QC program during assaying.
Qualified Person(s)
Avino’s projects in Durango, Mexico are under the geoscientific oversight of Michael F. O’Brien, P.Geo., Senior Principal Consultant, Red Pennant Communications, and under the supervision of Peter Latta, P.Eng, Avino’s VP, Technical Services, who are both qualified persons within the context of NI 43-101. Both have reviewed and approved the technical data in this news release.
About Avino
Avino is a silver producer from its wholly owned Avino Mine near Durango, Mexico. The Company’s silver, gold and copper production remains unhedged. The Company intends to maintain long term sustainable and profitable mining operations to reward shareholders and the community alike through our growth at the historic Avino Property and the strategic acquisition of the adjacent La Preciosa which was finalized in Q1 2022. Early in 2024, the Pre-feasibility Study on the Oxide Tailings Project was completed. This study is a key milestone in our growth trajectory. Avino has been included in the Toronto Stock Exchange’s 2025 TSX30™. Avino has distinguished itself by reaching the 5th position on the TSX30 2025 ranking. As part of Avino’s commitment to adopting sustainable practices, we have been operating a dry-stack tailings facility for more than two years with excellent results. We are committed to managing all business activities in a safe, environmentally responsible, and cost-effective manner, while contributing to the well-being of the communities in which we operate. We encourage you to connect with us on X (formerly Twitter) at @Avino_ASM and on LinkedIn at Avino Silver & Gold Mines. To view the Avino Mine VRIFY tour, please click here.
Note: All Avino Silver & Gold Mines Ltd. drill results are detailed in separate news releases and these releases are available on our website at www.avino.com and on our SEDAR profile at www.sedar+.com.
This news release contains “forward-looking information” and “forward-looking statements” (together, the “forward looking statements”) within the meaning of applicable securities laws and the United States Private Securities Litigation Reform Act of 1995, including the mineral resource estimate for the Company’s Avino Property, including La Preciosa, located near Durango in west-central Mexico (the “Avino Property”) with an effective date of October 16, 2023 and can be viewed within Avino’s latest technical report dated February 5, 2024 for the Pre-feasibility Study and references to Measured, Indicated Resources, and Proven and Probable Mineral Reserves referred to in this press release. This information and these statements, referred to herein as “forward-looking statements” are made as of the date of this document. Forward-looking statements relate to future events or future performance and reflect current estimates, predictions, expectations or beliefs regarding future events and include, but are not limited to, statements with respect to: (i) the estimated amount and grade of mineral reserves and mineral resources, including the cut-off grade; (ii) estimates of the capital costs of constructing mine facilities and bringing a mine into production, of operating the mine, of sustaining capital, of strip ratios and the duration of financing payback periods; (iii) the estimated amount of future production, both ore processed and metal recovered and recovery rates; (iv) estimates of operating costs, life of mine costs, net cash flow, net present value (NPV) and economic returns from an operating mine; and (v) the completion of the full Technical Report, including a Preliminary Economic Assessment, and its timing. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives or future events or performance (often, but not always, using words or phrases such as “expects”, “anticipates”, “plans”, “projects”, “estimates”, “envisages”, “assumes”, “intends”, “strategy”, “goals”, “objectives” or variations thereof or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative of any of these terms and similar expressions) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are made as of the date of this news release and the dates of technical reports, as applicable. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the future circumstances, outcomes or results anticipated in or implied by such forward-looking statements will occur or that plans, intentions or expectations upon which the forward-looking statements are based will occur. While we have based these forward-looking statements on our expectations about future events at the date that such statements were prepared, the statements are not a guarantee that such future events will occur and are subject to risks, uncertainties, assumptions and other factors which could cause events or outcomes to differ materially from those expressed or implied by such forward-looking statements.
Cautionary note to U.S. Investors concerning estimates of Mineral Reserves and Mineral Resources
All reserve and resource estimates reported by Avino were estimated in accordance with the Canadian National Instrument 43-101 and the Canadian Institute of Mining, Metallurgy and Petroleum (“CIM”) Definition Standards. The U.S. Securities and Exchange Commission (“SEC”) now recognizes estimates of “measured mineral resources,” “indicated mineral resources” and “inferred mineral resources” and uses new definitions of “proven mineral reserves” and “probable mineral reserves” that are substantially similar to the corresponding CIM Definition Standards. However, the CIM Definition Standards differ from the requirements applicable to US domestic issuers. US investors are cautioned not to assume that any “measured mineral resources,” “indicated mineral resources,” or “inferred mineral resources” that the Issuer reports are or will be economically or legally mineable. Further, “inferred mineral resources” are that part of a mineral resource for which quantity and grade are estimated on the basis of limited geologic evidence and sampling. Mineral resources which are not mineral reserves do not have demonstrated economic viability.
Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.
La Palma, CA October 27, 2025 –(PR.com)– Liminatus Pharma, Inc. (NASDAQ: LIMN), La Palma, CA, a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum of Understanding (MOU) with Capital Trust Group Limited (CTG), a New Zealand-based investment management firm, for a USD 30,000,000 equity financing via an earn-out mechanism to support Liminatus’s research and development of advanced immunotherapy assets.
Subject to completion of diligence and the negotiation of definitive agreements, CTG intends to subscribe to newly issued shares of Liminatus, subject to compliance with Nasdaq listing rules and U.S. securities laws. The subscription funds are expected to be remitted following the submission and effectiveness of a registration statement relating to the resale of the shares. Both parties aim to finalize and execute the definitive agreements in November 2025.
In addition to the equity investment, beginning in mid-November this year and subject to definitive agreements being signed, Liminatus and CTG plan to commence discussions for further strategic cooperation, including potential future digital bond financing programs.
“We believe that this MOU marks the beginning of a long-term partnership with CTG,” said Chris Kim, Chief Executive Officer of Liminatus Pharma. “The equity financing would strengthen our financial foundation.”
About Liminatus Pharma, Inc. (NASDAQ: LIMN)
Liminatus Pharma is a clinical-stage immuno-oncology company pioneering next-generation therapeutics, including its proprietary CD47-blockade antibody IBA101, designed to overcome the limitations of first-generation immune therapies in solid tumors.
About Capital Trust Group Limited (CTG)
Capital Trust Group is a New Zealand-based investment management and digital finance firm managing large-scale institutional and blockchain-enabled financing programs across healthcare, energy, and infrastructure sectors. CTG has the privilege of having General Chavalit Yongchaiyudh, the 22nd Prime Minister of Thailand, as one of its shareholders and an honorable advisor.
CTG Contact
Wasupit Wises, Director — wises@ctgprime.com, +66 61 7722142
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected equity investment, timing of definitive agreements, potential future digital bond programs, and anticipated financial and strategic benefits. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially from those described herein. Factors that may cause such differences include, among others, the ability to finalize and execute definitive agreements, regulatory and market conditions, and the availability of financing. Liminatus undertakes no obligation to update or revise any forward-looking statements, except as required by law.
Contact Information:
Liminatus Pharma, Inc
Chris Kim
213-273-5453 Contact via Email
www.liminatuspharma.com
Phoenix, AZ October 27, 2025 –(PR.com)– North Mountain Brewery is excited to announce their Executive Chef Jackie Abril-Carlile will be inducted into Les Disciples Escoffier USA this coming Tuesday, October 28, 2025. www.northmountainbrewing.com
This is an incredibly prestigious honor and North Mountain Brewery is proud of Chef Jackie’s major accomplishment.
To be inducted within Les Disciples Escoffier International, Chef Jackie was supported and endorsed by two distinguished sponsors: Chef Kareen Linton, 1st Delegate – Tampa Chapter and Chef Sebastien Giannini, President East Coast Chapter.
Chef Jackie has built a remarkable career as a Chef Instructor at Auguste Escoffier School of Culinary Arts, where she inspires and mentors the next generation of chefs. She holds a Bachelor’s in Culinary Arts and Service Management and Double Master’s Degrees in Business and Secondary Education. She is fluent in American Sign Language and was a teacher at the Phoenix School for the Deaf.
At North Mountain Brewery, Chef Jackie brings her background in classical French cooking to elevate the traditional pub food fare. Customer favorites include Pizza, Burgers, Lumpia, and similar MediterrAsian foods. She works closely with the Head Brewer, Rob Berkner, to highlight their Craft Beer in food items such as their house-made pizza dough.
Congratulations and Cheers to Chef Jackie Abrile-Carlile on her achievement and the well-deserved award.
Contact Information:
North Mountain Brewing Company
Candy Froogzo
602-861-5999 Contact via Email
www.northmountainbrewing.com
Robert Berkner- 602.380.7027
